An interventional study of Health-E You app in Sexually Transmitted Diseases, Sexual Health and Reproductive Health, sponsored by Johns Hopkins University. Recruiting at 8 sites in United States. Open to male participants aged 13 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 18th largest by planned enrollment of the 251 interventional ones that give a count, is one of 12 that started in 2026, is one of 190 with no phase, reaches primary completion later than 29 of the 41 other live ones, and was the 256th registered.
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
Browse Sexually Transmitted Diseases studies →32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
Westat · Sites in United States
Ages 13–24 · Men only · Healthy volunteers
Emory University · Sites in United States
Women only · Healthy volunteers
Westat · Sites in United States
Ages 13–29 · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 16–24
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.
This study: 13 Years to 21 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 29 · Phase 3 15 · Phase 4 12
First in 1993; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,752 is above the median of 449 across 426 interventional studies indexed under Sexually Transmitted Diseases.
Median enrollment 400 across the 251 interventional studies, 280 across the 30 observational. Of the 227 that completed or were terminated, 76 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 283 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 6 studies filed under Sexually Transmitted Diseases — fewer than ten, so there is no comparison to draw.
16 of the studies in Sexually Transmitted Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06183502Emory UniversityHIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men | 2026-11 |
| NCT07089836American Laboratory Products CompanyThis Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests. | 2026-12 |
| NCT07281599QurasenseEvaluation of the Q-Pad hrHPV Test System for Identifying Precancer | 2026-12-31 |
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
| NCT04372875Children's National Research InstituteHealth Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will involve evaluating Health-E You/Salud ìTu™, a web-based, pre-visit mobile app designed to support adolescent male youth and his clinicians in discussing sexual and reproductive health (SRH) topics and care. It will test its efficacy among male patients in clinical settings using a stepped wedge cluster randomized controlled trial design.
Health-E You is a pre-visit, web-based mobile app designed to support an adolescent male youth and his clinician in discussing SRH topics and care. It is shared with an adolescent patient prior to a clinic visit, and contains initial questions that subsequently provide the patient with individually-tailored health information. In addition, the app provides relevant information to the clinician on patients' SRH to optimize the time together as part of the visit. In total, the app takes approximately 10-15 minutes to complete. The purpose of this study is to evaluate the efficacy of the Health-E You app among male youth ages 13-21 using a cluster-randomized stepped-wedge design. A participant will be considered to have completed the study if the participant has completed the baseline assessment, worked through the app, an immediate follow-up assessment, and a 2-month post-visit follow-up assessment. The end of the study is defined as completion of the 2-month follow-up assessment. Hypotheses include compared to usual care, app users will have greater improvements in male method use behaviors (i.e., condom use) as well as knowledge about pregnancy and sexually transmitted infection (STI) prevention methods, male method use self-efficacy, improved knowledge about SRH care, self-efficacy talking with a clinician about SRH, beliefs about SRH promotion, and SRH care receipt.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
When clinics are in the control condition, patients will receive usual care. Before the visit eligible participants will receive a weblink to study information, and if agree to participate, the survey. The participants will not be presented Health-E You content and clinicians will not receive output to prime the visit; the participants will receive usual care as typical. Previously enrolled control males will not be enrolled during intervention periods to maintain the research study's integrity.
When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app. Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required.
Other: Health-E You app
When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app. Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required.
Correct Condom Use Self-Efficacy Scale
Higher score indicates greater self-efficacy for correct use of male condoms. This measure is scaled with range from 1 (very difficult) to 5 (very easy); range 7-35.
Time frame: Baseline, 24 hours after visit, 2-month follow-up
Perceived efficacy in patient-physician interactions (PEPPI)
Higher score indicates greater efficacy in patient-physician interaction about sexual and reproductive health. This measure is scaled with range from 1 (not at all confident) to 5 (very confident); range 5-25.
Time frame: Baseline, 24 hours after visit, 2-month follow-up
Frequency condom use
Measures frequency condom use with main \& non-main partners in past year and last 2 months
Time frame: Baseline, 2-month follow-up
Sexual and reproductive care receipt
Measures receipt of the recommended sexual and reproductive care package, based on national guidelines outlined by the Centers for Disease Control and Prevention (CDC) Office of Population Affairs (OPA) Quality Family Planning guidance \& American Academy of Pediatrics' Bright Futures
Time frame: Baseline, 24 hours after visit, 2-month follow-up
Plan to share: No — The final version of collected data will be made available within thirty (30) months after the end of the data collection. Data will be preserved and made accessible along with the data codebook and other relevant documentation via the chosen repository. The investigators will make the data available through restricted/controlled access. Open Inter-university Consortium for Political and Social Research's (ICPSR's) Traditional Restricted Data or Physical Data Enclave will be used for some or all of the data, with restricted access solely to approved researchers.
Started Jun 2026 (actual). Primary completion is estimated for May 2028, 23 months after the start.
Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 23 months is below that.
Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →